Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Little Italy Mercato brings fresh food and community to downtown San Diego - 2Vote In favor of Your Favored Sort Of Dress
- 3How Would You Like to Deal with Your Funds?
- 4Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme
- 5European nations criticise Israel’s death penalty plans
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- How to see the Ursids, the final meteor shower of 2025
- Which Switch Game Do You Suggest? Share Your Decision
- Young Muslims in Germany feel left out of Mideast debate, experts say
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
- Extraordinary Guinness World Records That Will Astound You
- Step by step instructions to Pick an Incineration Urn: Variables to Consider
